Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Dosing commenced in phase II adult AML trial of clofarabine

Jan. 16, 2004

SB-715992 enters broad phase II program for cancer

Jan. 16, 2004

Novel class of farnesyltransferase inhibitors synthesized by Abbott

Jan. 15, 2004

MPI-176716 produces tumor regression in animal models of ovarian cancer

Jan. 15, 2004

BioStratum and Novo Nordisk to develop antibodies to laminin-5 for cancer

Jan. 15, 2004

Eloxatin approved for first-line treatment of advanced colorectal cancer

Jan. 15, 2004

BMS scientists claim Eg5 inhibitors and their use in cancer therapy

Jan. 15, 2004

Pierre Fabre presents protein prenyltransferase inhibitors for cancer and other disorders

Jan. 15, 2004

A new phase II clinical trial to evaluate Davanat with 5-FU in refractory colorectal cancer

Jan. 14, 2004

Widespread use of alternative medicine in prostate cancer patients

Jan. 14, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 13, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...